Verrica Pharmaceuticals (VRCA) Enterprise Value (2017 - 2026)
Verrica Pharmaceuticals (VRCA) posted quarterly Enterprise Value of -$20.6 million for Q1 2026, up 30.39% year-over-year from -$15.8 million in Q1 2025, and up 31.67% quarter-over-quarter from -$30.1 million in Q4 2025.
Verrica Pharmaceuticals (VRCA) Enterprise Value (2017 - 2026) Analysis & Trends
Verrica Pharmaceuticals' Enterprise Value history runs 10 years deep, the most recent figure standing at -$20.6 million for Q1 2026.
- In Q1 2026, Enterprise Value rose 30.39% year-over-year to -$20.6 million; the TTM figure through Mar 2026 stood at -$20.6 million (up 30.39% YoY), while the FY2025 annual figure was -$30.1 million, up 34.93% from the prior year.
- Enterprise Value for Q1 2026 stood at -$20.6 million, up from -$30.1 million in the prior quarter.
- The five-year high for Enterprise Value was -$15.4 million in Q2 2025, with the low at -$84.3 million in Q3 2023.
- The 5-year median for Enterprise Value is -$34.3 million (2022), against an average of -$41.1 million.
- The sharpest annual moves came in 2023 and 2024: Enterprise Value sank 159.62% in 2023, then soared 72.72% in 2024.
- Verrica Pharmaceuticals' Enterprise Value stood at -$34.3 million in 2022, then sank by 102.92% to -$69.5 million in 2023, then surged by 33.38% to -$46.3 million in 2024, then surged by 34.93% to -$30.1 million in 2025, then soared by 31.67% to -$20.6 million in 2026.
- Business Quant data shows VRCA's Enterprise Value at -$20.6 million in Q1 2026, -$30.1 million in Q4 2025, and -$21.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.82 Bn | 131.97 Bn | 2.84 Bn | -7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 86.69 Bn | 78.70 Bn | 3.93 Bn | -7.99 Bn |
| 3 | Argenx Se | 65.23 Bn | 60.05 Bn | 1.37 Bn | -5.18 Bn |
| 4 | Moderna | 60.16 Bn | 55.02 Bn | 52.00 Mn | -5.14 Bn |
| 5 | BeOne Medicines | 42.16 Bn | 37.07 Bn | 1.53 Bn | -5.10 Bn |
| 6 | Alnylam Pharmaceuticals | 31.86 Bn | 28.55 Bn | 992.69 Mn | -3.31 Bn |
| 7 | BioNTech SE | 28.24 Bn | 9.85 Bn | 668.28 Mn | -18.39 Bn |
| 8 | Insmed | 27.53 Bn | 26.37 Bn | 358.27 Mn | -1.16 Bn |
| 9 | Royalty Pharma | 27.31 Bn | 26.47 Bn | - | 2.12 Bn |
| 10 | Verrica Pharmaceuticals | 100.13 Mn | 88.93 Mn | - | -11.20 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -11.20 Mn |
| Mar 31, 2026 | -20.60 Mn |
| Dec 31, 2025 | -30.15 Mn |
| Sep 30, 2025 | -21.10 Mn |
| Jun 30, 2025 | -15.40 Mn |
| Mar 31, 2025 | -29.60 Mn |
| Dec 31, 2024 | -46.33 Mn |
| Sep 30, 2024 | -23.00 Mn |
| Jun 30, 2024 | -31.93 Mn |
| Mar 31, 2024 | -48.90 Mn |
| Dec 31, 2023 | -69.55 Mn |
| Sep 30, 2023 | -84.31 Mn |
| Jun 30, 2023 | -55.14 Mn |
| Mar 31, 2023 | -59.95 Mn |
| Dec 31, 2022 | -34.27 Mn |
| Sep 30, 2022 | -32.47 Mn |
| Jun 30, 2022 | -45.43 Mn |
| Mar 31, 2022 | -50.41 Mn |
| Dec 31, 2021 | -15.75 Mn |
| Sep 30, 2021 | -20.44 Mn |